MFIM
TVRD

Mesirow Financial Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Mesirow Financial Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-588
Closed -$341K – 78
2019
Q4 		$341K Sell
588
-20
-3% -$14K 1.44% 41
2019
Q3 		$400K Sell
608
-321
-35% -$267K 1.68% 30
2019
Q2 		$719K Buy
929
+101
+12% +$71K 2.62% 3
2019
Q1 		$585K Buy
828
+264
+47% +$158K 2.32% 6
2018
Q4 		$264K Hold
564
– – 1.7% 29
2018
Q3 		$487K Sell
564
-45
-7% -$32.5K 2.51% 7
2018
Q2 		$420K Sell
609
-110
-15% -$55.9K 1.87% 23
2018
Q1 		$320K Buy
+719
New +$349K 1.35% 38

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mesirow Financial Investment Management's TVRD Position: Q1 2020 in Review

Mesirow Financial Investment Management sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 588 shares — an estimated $341K sold.

Mesirow Financial Investment Management first reported a position in TVRD in Q1 2018 and held it in 8 quarters. The position peaked at $719K in Q2 2019. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

  • Mesirow Financial Investment Management reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 588 Tvardi Therapeutics shares in Q1 2020, an estimated $341K.
  • Mesirow Financial Investment Management first reported a position in Tvardi Therapeutics in Q1 2018 and held it in 8 quarters.
  • Mesirow Financial Investment Management's Tvardi Therapeutics position peaked at $719K in Q2 2019.
  • 133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on Mesirow Financial Investment Management's 13F filing for Q1 2020, filed 9 Apr 2020.